Default company panoramic image
Logo

Argon Pharma S.L.

Biotech devoted to the development of innovative oral antitumor drugs of wide spectrum.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Barcelona Wine Bar & Restaurant, Temple Street, New Haven, CT, US
  • Currency EUR
  • Founded April 2008
  • Employees 2
  • Website argonpharma.eu

Company Summary

ARGON PHARMA is a biotech company created by technology transfer from the Hospital de Sant Pau de Barcelona and the University of Barcelona. Argon Pharma has the mission to develop new innovative therapies to provide solutions to unmet medical needs in the oncology field, and also to develop new technologies for drug delivery and diagnosis to improve current therapies, increasing patient welfare and bringing real benefits to patients.

Team

  • Default avatar
    Simo Schwartz Navarro
    Dr

    Degree and PhD in Medicine at UAB. Postdoctoral stay at the Burnham Institute, California. Since 2000 the group leader CIBBIM Nanomedicine (Hospital Vall d'Hebron), since 2007 he is the coordinator. Since 2011 is scientific deputy director of CIBER BBN and also technology transfer coordinator at CIBER BBN. He has been adviser of biotech companies, is the author of six patents, has been coordinator of over six collaborative projects.

  • Default avatar
    Maria Jesus Vicent Docon
    Dra

    Degree and PhD in Chemistry from the University of Castelló. Postdoctoral stays at the Centre for Polymer Therapeutics (Cardiff, UK) and the Institute Biomar, SA (Madrid). In 2006 he joined the Prince Felipe Research Centre in Valencia, where since 2006 he is group leader in the Polymer Therapeutics Laboratory and screening platform. Participated in collaborative projects, has several patents and is CEO of Polypeptide Therapeutic Solutions S.L

  • Default avatar
    Ramon Mangues Bafalluy
    Dr

    Degree and PhD in Pharmacy from the University of Navarra. Postdoctoral stay at the New York University Medical Center. Since 1998 he he is team leader at theResearch Institute of the Hospital of St. Sant Pau, and Since 2007 also at CIBER BBN in oncology and antitumor drugs. Member of the Executive Committee of the Instituto de Sant Pau. Has participated in collaborative projects and with the industry.

  • Default avatar
    Fernando Albericio Palomera
    Dr.

    Ph.D. in chemistry from the UB. Several postdoctoral stays in USA and France. He is Professor in the UB and Director of Research in Peptide Milligen / Biosearch (Boston, USA). He Professor of Organic Chemistry at UB and was director of the PCB until 2012. He leads a team at the IRB. He has more than 40 patents and has created several companies biotecnológicas.Es Doctor "Honoris Causa" from the University of Buenos Aires.

  • Default avatar
    Ramon Roca Puig
    Dr.

    Degree and Ph.D. in Biology from the UB. Postdoctoral stay at the ICR in London. In 2003 he joined the R&D center of Almirall taking part in drug discovery projects. In 2009 he joined the CIBER BBN as Project Manager, participating in collaborative projects. Since 2011 he is the CEO of Argon Pharma. He has a master's degree in leadership and management of science at UPF and participated in investment readiness (ESADE) and Growth academy (IESE) pr

  • Default avatar
    Oscar Peña Gulín
    Dr

    Degree and PhD in chemistry from the UB. Specialized in polymer chemistry, drug delivery and medicinal chemistry. He has made a postdoctoral stay at IRB in Barcelona. In 2009 he joined Argon Pharma and is currently the head of R&D and has 3 patents.

Advisors

  • Default avatar
    http://www.rcdslp.com/
    Lawyer
    Unconfirmed
    Default avatar
    http://ocontech.com/
    Accountant
    Unconfirmed